What Is Prolotherapy

Prolotherapy (short for proliferative therapy) is a regenerative injection technique in which a mild irritant solution is delivered directly into damaged or weakened ligaments, tendons, or joint capsules. The injected solution, most often concentrated dextrose, provokes a controlled inflammatory cascade at the injection site that stimulates the body to produce new collagen and repair connective tissue. The goal is to restore structural integrity to joints that have become unstable or painful due to ligament laxity or chronic tendon degeneration.

Chronic joint pain and ligament instability represent some of the most common reasons adults limit physical activity as they age. When a ligament or tendon is partially torn or chronically stretched, it may never fully heal on its own because connective tissue has limited blood supply and therefore limited access to the growth factors that drive repair. Over time, this structural weakness can cause compensatory movement patterns, accelerated cartilage wear, and progressive loss of mobility, all of which erode healthspan well before any organ-level disease appears.

Prolotherapy addresses this problem at the tissue level by restarting a healing process that stalled. Rather than masking pain with anti-inflammatory drugs (which can actually impair tissue repair) or relying on surgical reconstruction, the approach works with the body's existing repair machinery. For longevity-oriented individuals, maintaining structural resilience in load-bearing joints is not optional; it is a prerequisite for the resistance training, walking, and balance work that protect against sarcopenia, falls, and metabolic decline in later decades.

The core mechanism of prolotherapy centers on controlled provocation of the inflammatory cascade. When a concentrated dextrose solution (typically 12.5% to 25%) is injected into the enthesis (the point where a tendon or ligament attaches to bone), it creates an osmotic stress on local cells. This stress, combined with the minor tissue disruption from the needle itself, initiates the same sequence of events the body uses to heal an acute injury: platelet aggregation, release of platelet-derived growth factor (PDGF), recruitment of macrophages, and activation of fibroblasts.

The fibroblasts are the key players. Once activated, they begin synthesizing new type I and type III collagen, the structural proteins that give ligaments and tendons their tensile strength. Over four to six weeks, this new collagen matures and cross-links, gradually thickening and tightening the treated tissue. The result is a ligament or tendon that is structurally denser than it was before treatment. Ultrasound and MRI studies in small trials have shown measurable increases in ligament cross-sectional area following a series of dextrose injections.

Prolotherapy differs from corticosteroid injections in a fundamental way. Corticosteroids suppress inflammation and provide short-term pain relief, but they also inhibit collagen synthesis and can weaken connective tissue with repeated use. Prolotherapy intentionally amplifies the early inflammatory phase, which is why patients are instructed to avoid anti-inflammatory medications (NSAIDs) around the time of treatment. The temporary increase in soreness is the mechanism at work, not a side effect to be suppressed.

A prolotherapy session begins with a focused physical examination in which the practitioner palpates specific ligament and tendon attachment points to identify areas of tenderness and laxity. Once target sites are mapped, the skin is cleaned and a series of injections are delivered using a fine needle. Each injection deposits a small volume (typically 0.5 to 1 mL) of the proliferant solution, usually dextrose mixed with lidocaine or procaine for local anesthesia. A single session may involve anywhere from five to thirty or more injections depending on the number of sites being treated.

The injections are uncomfortable, and patients commonly describe a deep aching or pressure sensation at each site. The entire procedure typically takes 15 to 30 minutes. Afterward, the treated area will feel sore and may swell mildly. Most practitioners recommend icing sparingly (or not at all, since the inflammatory response is intentional) and using acetaminophen rather than NSAIDs for discomfort. Activity is encouraged within tolerance, but heavy loading of the treated joint is generally avoided for the first five to seven days. The post-injection soreness typically resolves within a week, and patients often notice gradual improvement in baseline pain and stability over the following three to six weeks.

A standard prolotherapy treatment course consists of three to six sessions, each separated by three to six weeks. This spacing allows each round of injected proliferant to trigger a complete inflammatory and collagen-building cycle before the next session adds another layer of tissue repair. Some patients experience meaningful relief after two or three sessions, while more chronic or structurally complex cases may require six or more rounds before the tissue has rebuilt to a functional threshold.

After the initial treatment series, many patients do not require ongoing maintenance. If symptoms recur months or years later, a single booster session may be sufficient. The total duration from first injection to final assessment of outcomes typically spans three to nine months. Because collagen maturation and cross-linking continue for several months after the last injection, practitioners generally wait at least two to three months after the final session before making definitive judgments about whether the treatment course was adequate.

In the United States, a single prolotherapy session typically costs between $150 and $500, depending on the number of injection sites, the practitioner's experience, and geographic location. Sessions treating multiple joints or requiring a large number of injections may cost more. A full treatment course of three to six sessions therefore ranges from roughly $450 to $3,000 total. Some practitioners offer package pricing that reduces the per-session cost when patients commit to a full treatment series upfront.

Most private health insurance plans do not cover prolotherapy, classifying it as experimental or investigational. Patients should verify whether their health savings account or flexible spending account can be applied. A small number of integrative medicine practices that accept Medicare or Medicaid may bill prolotherapy under broader injection codes, but this is not standard. Compared to surgical alternatives for chronic joint instability, prolotherapy is substantially less expensive, though the out-of-pocket nature of the cost can be a barrier for patients requiring extended treatment courses.

The evidence base for prolotherapy is mixed and evolving, with quality varying significantly by condition treated. For chronic low back pain associated with sacroiliac joint laxity, several randomized controlled trials have compared dextrose prolotherapy to saline injections or exercise-only controls, with some showing statistically significant improvements in pain and function over six to twelve months. Systematic reviews have generally concluded that evidence is favorable for knee osteoarthritis and lateral epicondylosis (tennis elbow), where multiple trials have shown dextrose injections outperforming both watchful waiting and saline controls. The largest and most methodologically rigorous trials have been conducted in knee osteoarthritis, where dextrose prolotherapy has demonstrated improvements in pain scores and physical function sustained at one year.

However, the overall body of evidence remains limited by small sample sizes, heterogeneous injection protocols, and difficulty with blinding (since patients can often distinguish between active treatment and saline injections based on post-injection soreness). For many commonly treated conditions, including rotator cuff tendinopathy and Achilles tendinopathy, evidence consists primarily of case series and observational studies rather than well-powered randomized trials. No large multicenter trial has established prolotherapy as a standard of care for any condition, and professional orthopedic societies have not issued formal endorsements. The therapy is recognized within integrative and sports medicine circles but remains outside mainstream orthopedic practice in most countries.

Prolotherapy is generally well tolerated, with the most common adverse effects being temporary soreness, swelling, and stiffness at injection sites lasting two to five days. Serious complications are rare but include infection at the injection site, nerve irritation, and allergic reaction to the injectate. Pneumothorax is a known risk when injections are placed near the thoracic spine or rib attachments, making practitioner skill and anatomical knowledge essential. Prolotherapy is not appropriate for joints with active infection, fractures, or complete tendon ruptures that require surgical repair. Individuals taking anticoagulants or those with bleeding disorders should discuss risks with their practitioner, as the procedure involves multiple needle insertions into well-vascularized tissue.